H
HighTide Therapeutics
Focuses on developing multifunctional therapies for metabolic and digestive diseases
About HighTide Therapeutics
HighTide Therapeutics is a globally integrated biopharmaceutical company that specializes in developing multifunctional, multi-targeted therapies for metabolic and digestive diseases. The company operates in the biotech industry, focusing on patient-centric drug development to bring optimal benefits to patients. HighTide's primary market includes patients suffering from metabolic and digestive diseases, particularly Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM).
Read full description
The company's business model revolves around the research, development, and commercialization of innovative drugs. HighTide is currently conducting a Phase 2b clinical trial for its drug, Berberine Ursodeoxycholate (HTD1801), which is designed to treat NASH. The company generates revenue through the successful development and subsequent sale of its pharmaceutical products.
HighTide has been invited to present at various international conferences, showcasing its research and development progress. This not only helps in gaining recognition but also attracts potential investors and partners. The company's vision is to become a leading and respected biotech company globally, emphasizing simplicity, resilience, and a win/win mindset.
At a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Shenzhen, China
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 44.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning HighTide Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VCOther financing | Dec 2023 | $14M | — | Hebei Cangzhou Chuangrong | ↗ |
| SERIES COther financing | Jan 2023 | $107M | $428M | CDIB Capital Group · Yufeng Shengtai Investment · Yuexiu Industrial Fund | ↗ |
Growth signals
Latest recorded traffic for HighTide Therapeutics is 3.9K monthly website visits, up 1047.1% over the last three months. HighTide Therapeutics's team declined 15.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
CDIB Capital Group- YIYufeng Shengtai Investment
- YFYuexiu Industrial Fund
- HCHebei Cangzhou Chuangrong
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about HighTide Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See HighTide Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.